{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:37:17Z","timestamp":1792859837437,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.autrev.2026.104155","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:47Z","timestamp":1785510707000},"page":"104155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thyroid eye disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Botrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Rugani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Novella","family":"Maglionico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104155_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0010","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0025","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County","volume":"92","author":"Bartley","year":"1994","journal-title":"Minnesota Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.autrev.2026.104155_bb0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0035","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0040","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.autrev.2026.104155_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2026.104155_bb0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/bjo-2022-322442","article-title":"Presentation of Graves\u2019 orbitopathy within European Group On Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)","volume":"108","author":"Schuh","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0055","doi-asserted-by":"crossref","unstructured":"Oeverhaus M, Winkler L, St\u00e4hr K, Daser A, Bechrakis N, St\u00f6hr M, et al. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis. Front Endocrinol (Lausanne). 202;14:1160172. doi:https:\/\/doi.org\/10.3389\/fendo.2023.1160172.","DOI":"10.3389\/fendo.2023.1160172"},{"key":"10.1016\/j.autrev.2026.104155_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves\u2019 disease (with or without ophthalmopathy): Review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.autrev.2016.09.009","article-title":"The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2265.2007.02854.x","article-title":"Susceptibility genes in Graves\u2019 ophthalmopathy: searching for a needle in a haystack?","volume":"67","author":"Bednarczuk","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.295.6599.634","article-title":"Is endocrine ophthalmopathy related to smoking?","volume":"295","author":"H\u00e4gg","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.autrev.2026.104155_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: The fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jc.2006-1824","article-title":"Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link","volume":"92","author":"Cawood","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0095","doi-asserted-by":"crossref","first-page":"4676289","DOI":"10.1155\/2016\/4676289","article-title":"Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves\u2019 Ophthalmopathy","volume":"2016","author":"Kau","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.autrev.2026.104155_bb0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eprac.2020.11.011","article-title":"Risk Factors of Thyroid Eye Disease","volume":"27","author":"Lee","year":"2021","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.autrev.2026.104155_bb0110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2017.0430","article-title":"High Serum Cholesterol Is a Novel Risk Factor for Graves\u2019 Orbitopathy: Results of a Cross-Sectional Study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2026.104155_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104155_bb0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy","volume":"44","author":"Nicol\u00ec","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2026.104155_bb0125","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s40618-023-02085-5","article-title":"The phenotype of Graves\u2019 orbitopathy is associated with thyrotropin receptor antibody levels","volume":"46","author":"Sari\u0107 Matutinovi\u0107","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2026.104155_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, Natural History, Risk Factors, and Prevention of Graves\u2019 Orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104155_bb0135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0140","doi-asserted-by":"crossref","first-page":"7453260","DOI":"10.1155\/2019\/7453260","article-title":"Immunological Aspects of Graves\u2019 Ophthalmopathy","volume":"2019","author":"\u0141acheta","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2026.104155_bb0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2265.2003.01708.x","article-title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves\u2019 ophthalmopathy patients","volume":"58","author":"Wakelkamp","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0150","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","article-title":"Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy","volume":"24","author":"Prabhakar","year":"2003","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104155_bb0155","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 Receptor Cross Talk in Graves\u2019 Ophthalmopathy Pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0160","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","article-title":"Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor","volume":"26","author":"Iyer","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0170","doi-asserted-by":"crossref","unstructured":"Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest 2021;44(4):703-712. doi:https:\/\/doi.org\/10.1007\/s40618-020-01380-9. Epub 2020 Aug 4. Erratum in: J Endocrinol Invest 2022;45:233. doi:https:\/\/doi.org\/10.1007\/s40618-020-01380-9.","DOI":"10.1007\/s40618-020-01380-9"},{"issue":"9","key":"10.1016\/j.autrev.2026.104155_bb0175","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/thy.2007.0404","article-title":"Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy","volume":"18","author":"Smith","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2026.104155_bb0180","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.autrev.2019.05.004","article-title":"Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves\u2019 disease and ophthalmopathy","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0185","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104155_bb0190","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104155_bb0195","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2014.08.025","article-title":"Extra-ocular muscle cells from patients with Graves\u2019 ophthalmopathy secrete \u03b1 (CXCL10) and \u03b2 (CCL2) chemokines under the influence of cytokines that are modulated by PPAR\u03b3","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0200","first-page":"776","article-title":"Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy","volume":"85","author":"Aniszewski","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0205","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0210","doi-asserted-by":"crossref","first-page":"e4037","DOI":"10.1210\/clinem\/dgac415","article-title":"Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy","volume":"107","author":"Fernando","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2018-01493","article-title":"Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy","volume":"104","author":"Smith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0220","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.4049\/jimmunol.1800259","article-title":"Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Graves\u2019 Disease","volume":"200","author":"Fernando","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104155_bb0225","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgaa959","article-title":"Slit2 Regulation of Hyaluronan and Cytokine Synthesis in Fibrocytes in Thyroid-associated Ophthalmopathy","volume":"106","author":"Antonelli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0230","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0235","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101773","article-title":"Chemokines in thyroid autoimmunity","volume":"37","author":"Ferrari","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103238","article-title":"Graves\u2019 disease induced by IFN-\u03b21a therapy: A case report, review of literature and new insights into the pathogenesis","volume":"22","author":"Patrizio","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0250","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves\u2019 ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0255","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves\u2019 disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0265","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1089\/thy.2012.0485","article-title":"Increase of interferon-\u03b3 inducible CXCL9 and CXCL11 serum levels in patients with active Graves\u2019 disease and modulation by methimazole therapy","volume":"23","author":"Antonelli","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2026.104155_bb0270","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0275","series-title":"Graves\u2019 Orbitopathy: A Multidisciplinary Approach - Questions and Answers","article-title":"Clinical manifestations","author":"Dickinson","year":"2017"},{"issue":"4","key":"10.1016\/j.autrev.2026.104155_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2006.094607","article-title":"Clinical features of dysthyroid optic neuropathy: a European Group on Graves\u2019 Orbitopathy (EUGOGO) survey","volume":"91","author":"McKeag","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0285","first-page":"568","article-title":"Dysthyroid optic neuropathy without extraocular muscle involvement","volume":"20","author":"Anderson","year":"1989","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.autrev.2026.104155_bb0290","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of Graves Thyroidal and Extrathyroidal Disease: An Update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0295","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","article-title":"Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy","volume":"93","author":"Eckstein","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IIO.0000000000000289","article-title":"A Review of Imaging Modalities in Thyroid-associated Orbitopathy","volume":"59","author":"North","year":"2019","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.autrev.2026.104155_bb0305","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","article-title":"Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy","volume":"62","author":"Terwee","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0315","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jcem-44-1-203","article-title":"Modification of the classification of the eye changes of Graves\u2019 disease: recommendations of the Ad Hoc Committee of the American Thyroid Association","volume":"44","author":"Werner","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0325","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1450107","article-title":"Imaging in thyroid-associated orbitopathy","volume":"145","author":"Kahaly","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12902-019-0340-0","article-title":"Efficacy of 99mTc-DTPA SPECT\/CT in diagnosing Orbitopathy in graves\u2019 disease","volume":"19","author":"Szumowski","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.autrev.2026.104155_bb0340","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(93)31607-6","article-title":"A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy","volume":"100","author":"Prummel","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2026.104155_bb0345","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0004-27302011000300002","article-title":"Ultrasonography compared to magnetic resonance imaging in thyroid-associated Graves\u2019 ophthalmopathy","volume":"55","author":"Vlainich","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.autrev.2026.104155_bb0350","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1034\/j.1600-0420.2003.00037.x","article-title":"Ultrasonically measured horizontal eye muscle thickness in thyroid associated orbitopathy: cross-sectional and longitudinal aspects in a Danish series","volume":"81","author":"Fledelius","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.autrev.2026.104155_bb0355","first-page":"57","article-title":"The relationship between Graves\u2019 ophthalmopathy and dry eye syndrome","volume":"9","author":"Selter","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0360","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0161-6420(02)01041-2","article-title":"Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection","volume":"109","author":"Uddin","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2026.104155_bb0365","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40618-015-0255-1","article-title":"Total thyroid ablation in Graves\u2019 orbitopathy","volume":"38","author":"Menconi","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2026.104155_bb0370","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/jc.2013-3093","article-title":"Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves\u2019 orbitopathy (GO): a prospective, randomized, single-blind clinical trial","volume":"99","author":"Moleti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0375","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism. The Thyroid Study Group","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104155_bb0380","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","article-title":"Cigarette smoking and treatment outcomes in Graves ophthalmopathy","volume":"129","author":"Bartalena","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0385","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0390","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.autrev.2026.104155_bb0395","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jfo.2020.08.029","article-title":"Oral selenium improved the disease activity in patients with mild Graves\u2019 orbitopathy","volume":"44","author":"Almanza-Monterrubio","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0400","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40265-018-1045-9","article-title":"Current and Emerging Treatment Strategies for Graves\u2019 Orbitopathy","volume":"79","author":"Genere","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104155_bb0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.autrev.2026.104155_bb0410","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0415","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/ct.2018;30.246-250","article-title":"A Validated Tool Can Predict Risk or Nonrisk of Graves\u2019 Orbitopathy During Antithyroid Drug Treatment of Hyperthyroid Graves\u2019 Disease","volume":"30","author":"Orgiazzi","year":"2018","journal-title":"Clin Thyroidol"},{"key":"10.1016\/j.autrev.2026.104155_bb0425","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","article-title":"Dose of intravenous steroids and therapy outcome in Graves\u2019 orbitopathy","volume":"34","author":"Zang","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2026.104155_bb0430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0435","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/thy.2015.0061","article-title":"Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves\u2019 Orbitopathy","volume":"25","author":"Sisti","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2026.104155_bb0440","doi-asserted-by":"crossref","first-page":"1978590","DOI":"10.1155\/2018\/1978590","article-title":"Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves\u2019 Orbitopathy","volume":"2018","author":"Mi\u015bkiewicz","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0445","first-page":"102","article-title":"Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial","volume":"85","author":"Kahaly","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0450","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for graves\u2019 orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0455","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2013-1804","article-title":"Potential utility of rituximab for Graves\u2019 orbitopathy","volume":"98","author":"Salvi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0460","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0465","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/IOP.0000000000001949","article-title":"Risk Factors for New Onset Diplopia After Graduated Orbital Decompression","volume":"37","author":"St\u00e4hr","year":"2021","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.autrev.2026.104155_bb0470","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2021.0411","article-title":"The Effect of Ophthalmic Surgery for Graves\u2019 Orbitopathy on Quality of Life: A Systematic Review and Meta-Analysis","volume":"32","author":"Woo","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2026.104155_bb0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/a-1325-9061","article-title":"Eyelid Surgery in Graves' Orbitopathy","volume":"238","author":"Hintschich","year":"2021","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.autrev.2026.104155_bb0480","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12886-024-03749-3","article-title":"Comparative effectiveness of various orbital decompression techniques in treating thyroid-associated ophthalmopathy: a systematic review and meta-analysis","volume":"24","author":"Guo","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0485","article-title":"Dry Eye Disease Prevalence and Associated Risk Factors Among the Middle East Population: A Systematic Review and Meta-Analysis","volume":"16","author":"Mohamed","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2026.104155_bb0490","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/IOP.0000000000002852","article-title":"Botulinum Toxin Treatment in Thyroid Eye Disease: A Systematic Review and Meta-analysis","volume":"41","author":"Zong","year":"2025","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.autrev.2026.104155_bb0495","first-page":"13","article-title":"High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0500","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104155_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101366","article-title":"Novel therapies for thyroid autoimmune diseases: An update","volume":"34","author":"Ferrari","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0510","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104155_bb0515","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0520","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0525","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/phar.2111","article-title":"Efficacy and Safety of Rituximab for the Treatment of Graves\u2019 Orbitopathy: A Meta-analysis of Randomized Controlled Trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2026.104155_bb0530","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-Dose Rituximab for Active Moderate to Severe Graves\u2019 Orbitopathy Resistant to Conventional Treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2026.104155_bb0535","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0540","doi-asserted-by":"crossref","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72:ii111-5. doi:https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576.","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"10.1016\/j.autrev.2026.104155_bb0545","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2026.104155_bb0550","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104155_bb0555","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/jamadermatol.2024.0344","article-title":"Tofacitinib Treatment for Pretibial Myxedema","volume":"160","author":"Wang","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2026.104155_bb0560","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaophthalmol.2025.3974","article-title":"Tofacitinib for Refractory Thyroid Eye Disease","volume":"143","author":"Ghahvehchian","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0565","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104155_bb0570","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104155_bb0575","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0580","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","article-title":"Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves\u2019 Ophthalmopathy, a Report of Three Cases","volume":"28","author":"Maldiney","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2026.104155_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.654473","article-title":"Cytokines as Targets of Novel Therapies for Graves\u2019 Ophthalmopathy","volume":"12","author":"Fallahi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104155_bb0590","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IOP.0000000000002573","article-title":"Efficiency and Safety of Tocilizumab for the Treatment of Thyroid Eye Disease: A Systematic Review","volume":"40","author":"Duarte","year":"2024","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.autrev.2026.104155_bb0595","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104155_bb0600","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0605","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s40123-025-01255-3","article-title":"Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials","volume":"14","author":"Ezra","year":"2025","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.autrev.2026.104155_bb0610","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104155_bb0615","doi-asserted-by":"crossref","unstructured":"Navarrete VM, Miera FJTS de, Hermosilla AMG, Reinoso PM, Dom\u00ednguez MJM, Venegas JJP. Ab1315 Sarilumab in Patients with Refractory Graves\u2019 Orbitopathy. Effectiveness and Safety in a Series of Cases in Clinical Practice. Ann Rheum Dis 2022;81:1764\u20131765. doi:https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.4039.","DOI":"10.1136\/annrheumdis-2022-eular.4039"},{"key":"10.1016\/j.autrev.2026.104155_bb0620","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41598-026-35682-4","article-title":"Sarilumab in the management of Graves orbitopathy with low clinical activity scores","volume":"16","author":"P\u00e9rez-Moreiras","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104155_bb0625","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04737330."},{"key":"10.1016\/j.autrev.2026.104155_bb0630","first-page":"dgaf655","article-title":"Secukinumab in Moderate-to-Severe Graves\u2019 Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study","author":"Wolf","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0635","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05394857."},{"key":"10.1016\/j.autrev.2026.104155_bb0640","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14712598.2023.2172328","article-title":"Teprotumumab for the treatment of thyroid eye disease","volume":"23","author":"Fallahi","year":"2023","journal-title":"Expert Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2026.104155_bb0645","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0650","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0655","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104155_bb0665","unstructured":"https:\/\/www.gov.uk\/government\/news\/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0675","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0680","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104155_bb0685","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.autrev.2026.104155_bb0690","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/TCRM.S303057","article-title":"Efficacy and Safety of Teprotumumab in Thyroid Eye Disease","volume":"17","author":"Teo","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.autrev.2026.104155_bb0695","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2026.104155_bb0700","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04583735 (2024)."},{"key":"10.1016\/j.autrev.2026.104155_bb0705","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05002998 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0715","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05176639 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0720","first-page":"29","article-title":"THRIVE-2 phase 3 trial of Veligrotug (VRDN-001) in chronic thyroid eye disease (TED): Efficacy and safety at 15 weeks","volume":"110","author":"Rodien","year":"2025","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.autrev.2026.104155_bb0725","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06384547 (2026)."},{"key":"10.1016\/j.autrev.2026.104155_bb0735","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.autrev.2026.104155_bb0740","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05276063 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0745","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06112340 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0750","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06401044 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0755","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.2040","article-title":"Preliminary Safety and Efficacy of Subcutaneous Lonigutamab (anti-IGF-1R) from a Phase 1\/2 Proof of Concept Study in Patients with Thyroid Eye Disease","volume":"8","author":"Ugradar","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.autrev.2026.104155_bb0760","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0765","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-Results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0770","doi-asserted-by":"crossref","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Set al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab 2023;108:3122-3134. doi:https:\/\/doi.org\/10.1210\/clinem\/dgad381.","DOI":"10.1210\/clinem\/dgad381"},{"key":"10.1016\/j.autrev.2026.104155_bb0790","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06307613 (2025)."},{"key":"10.1016\/j.autrev.2026.104155_bb0795","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy?","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"A randomized controlled trial Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2026.104155_bb0800","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group On Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104155_bb0805","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s40618-020-01479-z","article-title":"Change in newly diagnosed Graves\u2019 disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression","volume":"44","author":"Ippolito","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2026.104155_bb0810","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/clinem\/dgaf009","article-title":"Treatment of Hyperthyroidism in Graves\u2019 Disease Complicated by Thyroid Eye Disease","volume":"110","author":"Bartalena","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104155_bb0815","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12020-023-03680-5","article-title":"Statins and thyroid eye disease (TED): a systematic review","volume":"85","author":"Malboosbaf","year":"2024","journal-title":"Endocrine"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:03:19Z","timestamp":1792857799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":156,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1568997226001692"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104155","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid eye disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104155"}}